Nasdaq cprx
Catalyst is undervalued at its current valuation with a P/E GAAP (TTM) of 8.13, when compared against the sector median of 36.43. Catalyst Pharmaceuticals ( NASDAQ: CPRX) is a small cap ...Catalyst Pharmaceutical (CPRX) closed at $16.60 in the latest trading session, marking a -0.12% move from the prior day. This move was narrower than the S&P 500's daily loss of 0.7%.
Did you know?
Most readers would already be aware that Catalyst Pharmaceuticals' (NASDAQ:CPRX) stock increased significantly by 9.4% over the past month. Since the market usually pay for a company’s long-term ...Catalyst Pharmaceuticals, Inc. (CPRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Catalyst Pharmaceuticals, Inc ...Catalyst Pharmaceuticals, Inc. (CPRX.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Catalyst Pharmaceuticals, ...Analysts Set Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Target Price at $24.75 americanbankingnews.com - November 13 at 1:28 AM: Catalyst Pharmaceuticals (NASDAQ:CPRX) Shares Up 5% americanbankingnews.com - November 12 at 4:00 AM: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2023 Earnings …CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023 7:46 p.m. EST Delayed quote $ 13.68 -0.13 -0.94% After Hours...Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and a beta of 1.11. …Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 14.05 per share at the end of the most recent trading day (a -1.13 % change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 1.54B.Is a component of indices and it is traded on NASDAQ exchange. The company belongs in …This value model looks for companies with high return on capital and earnings yields. CATALYST PHARMACEUTICALS INC ( CPRX) is a small-cap value stock in the Biotechnology & Drugs industry. The ...A high-level overview of Catalyst Pharmaceuticals, Inc. (CPRX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Feb 27, 2023 · For the last reported quarter, Catalyst came out with earnings of $0.20 per share versus the Zacks Consensus Estimate of $0.19 per share, representing a surprise of 5.26%. For the previous quarter ... Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Nov 30, 2023 · The stock price of Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) has plunged by -1.13 when compared to previous closing price of 14.21, but the company has seen a 2.26% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-11-09 that Catalyst (CPRX) reports mixed third-quarter results. Firdapse and Fycompa sales […] Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Catalyst Pharmaceuticals (NASDAQ: CPRX) $14.05 (-1.1%) -$0.16 Price as of November 29, 2023, 4:00 p.m. ET Financial Health Earnings Transcripts Related Stocks Key Data Points Current Price $14.05...Find the latest SEC Filings data for CataCatalyst Pharmaceuticals' CEO is Pat McEnany, appointed in Dec 28, 2022 · Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company, focused on developing and commercializing therapies for patients with rare debilitating ... Apr 18, 2023 · cagkansayin. In my last coverage, I dis Catalyst Pharmaceuticals, Inc. (CPRX) is a commercial-stage biopharmaceutical company that develops and commercializes therapies for patients with rare neuromuscular and neurological diseases.The company reported a solid second-quarter result, with total revenues growing 87.5% year-over-year to an all-time high of … CPRX: NASDAQ (Stock) CATALYST PHARMACEUTICALS, INC. DEC 01, 11:00 AM
cagkansayin. In my last coverage, I discussed Teva Pharmaceutical Industries Limited's generic ANDA challenge to Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Firdapse, and the history …Long trade in CPRX CPRX is the #1 stock in the biotech group by almost every metric. The table on the chart shows its ranking out of all 795 biotech stocks by 3 metrics from IBD's MarketSmith. Sales and earnings are surging and the rate at which both are growing has increased in each of the last 4 quarters. The stoCPRX is the #1 stock in the ...NasdaqCM:CPRX Insider Trading Volume August 29th 2021. I will like Catalyst Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of growing companies with ...Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com. CPRX U.S.: Nasdaq Catalyst Pharmaceuticals Inc. Watch list NEW Set a price target alert After Hours Last Updated: Nov 17, 2023 7:46 p.m. EST Delayed quote $ 13.68 -0.13 -0.94% After Hours...
Anyone interested in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) should probably be aware that the Chief Commercial Officer, Jeffrey Del Carmen, recently divested US$199k worth of shares in the ...Oct 13, 2023 · U.S. FDA Assigned Target Action Date of June 4, 2024. CORAL GABLES, Fla., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced ... CPRX - Catalyst Pharmaceuticals Inc (NASDAQ) Stock - Earnings History.…
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. (Nasdaq: CPRX) announced today that it has entered into de. Possible cause: Find the latest dividend history for Catalyst Pharmaceuticals, Inc. Common Stock.
09/26/2022. 5.23%. 95,058,928. 4,970,704. 7,496,361. 1. Data brought to you by Benzinga APIs. Looking for the most shorted stocks? Short interest for Catalyst Pharmaceuticals gives investors a ...Catalyst Pharmaceutical (CPRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2022. This widely-known ...Find the latest press releases from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.
To wit, the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) share price has soared 514% over five years. This just goes to show the value creation that some businesses can achieve.Catalyst Pharmaceuticals (NASDAQ:CPRX) has recently experienced a trading halt on the Nasdaq exchange, leaving investors eagerly awaiting pending news. The specific cause for this halt remains undisclosed, however, it is widely anticipated that it revolves around the potential disclosure of significant information.Shares of NASDAQ:CPRX opened at $14.82 on Monday. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 28.50 and a beta of 1.11. The stock’s 50-day simple moving ...
Their CPRX share price targets range from $24.00 to $27.00 Catalyst Pharmaceuticals Inc (CPRX) Stock Price & News - Google Finance. Home CPRX • NASDAQ. Catalyst Pharmaceuticals Inc. Follow. Share. $14.06. After Hours: $13.71. … Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) – ZacksFintel reports that on August 22, 2023, Cantor Fitzgerald reitera Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms.U.S. FDA Assigned Target Action Date of June 4, 2024. CORAL GABLES, Fla., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced ... The stock price of Catalyst Pharmaceuticals Inc (NASDAQ: CPR (NASDAQ:CPRX), announced on June 20, 2023 [1]. The proceeds from the agreement extend Santhera's cash reach into 2025. Together with the expected income ... Find the latest SEC Filings data for Catalyst PharmaceuticalsSep 21, 2022 · The average CPRX stock price target of $16.70 pBack to CPRX Overview About Latest Pre-Market Trades Nasda Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets. 09/26/2022. 5.23%. 95,058,928. 4,970,704. 7,496,361. Catalyst Pharmaceutical (CPRX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance ... Catalyst Pharmaceuticals CPRX has had a good run this yea[Then look at the Catalyst Pharmaceuticals, Inc. (NASDAQ:CPCatalyst Pharmaceuticals Inc share price live 13.860, this pag Find the latest news headlines from Catalyst Pharmaceuticals, Inc. Common Stock (CPRX) at Nasdaq.com.Nasdaq News: This is the News-site for the company Nasdaq on Markets Insider Indices Commodities Currencies Stocks